Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Room For HCV-Focused Start-Ups If The Technology Is Truly Novel

This article was originally published in Start Up

Executive Summary

Hepatitis C has been the focus of some of biopharma’s most expensive deals the past couple years. In the wake of the licensing, IPO, and M&A frenzy, not many new start-ups have emerged, but there are a still a few niches to fill if entrepreneurs can find funding.

You may also be interested in...

Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing

Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

Hikma Proves Resilient In 2020 Despite Some Bumpy Launches

Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts